Compare CAPR & ZD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | ZD |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2011 | 1999 |
| Metric | CAPR | ZD |
|---|---|---|
| Price | $3.93 | $53.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 7 |
| Target Price | ★ $44.63 | $39.71 |
| AVG Volume (30 Days) | ★ 5.4M | 582.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 17.49 |
| Revenue | N/A | ★ $1,364,028,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.31 | $2.16 |
| P/E Ratio | ★ N/A | $3.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $22.45 |
| 52 Week High | $40.37 | $58.06 |
| Indicator | CAPR | ZD |
|---|---|---|
| Relative Strength Index (RSI) | 13.94 | 53.28 |
| Support Level | N/A | $50.68 |
| Resistance Level | $6.81 | $54.86 |
| Average True Range (ATR) | 0.97 | 2.21 |
| MACD | -0.33 | -0.17 |
| Stochastic Oscillator | 5.63 | 37.99 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Ziff Davis Inc is a digital media and internet company operating a portfolio of brands across technology, shopping, gaming and entertainment, health and wellness, connectivity, and cybersecurity. The company has five reportable segments. The Technology & Shopping segment generates revenue from advertising and commerce content. The Gaming & Entertainment segment provides content, subscriptions, and digital storefront services. The Health & Wellness segment offers digital tools and content for health management. The Connectivity segment provides data and analytics solutions for network performance. The Cybersecurity & Martech segment delivers cloud-based software for security and marketing. It generates the majority of its revenue from the Health & Wellness segment.